Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.51 |
| ▸ | PIK3C2B | O00750 | 14/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.47 |
| ▸ | MTOR | P42345 | 12/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736616 | 0.92 | PIK3CD (0.48) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736614 | 0.87 | PIK3CD (0.46) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736858 | 0.86 | PIK3CD (0.51) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736881 | 0.85 | PIK3CD (0.46) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL21078623 | 0.84 | PIK3CD (0.45) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19737016 | 0.83 | PIK3CD (0.43) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736873 | 0.81 | PIK3CD (0.60) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736880 | 0.80 | PIK3CD (0.60) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736878 | 0.80 | PIK3CD (0.49) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR | |
| SCHEMBL19736644 | 0.80 | PIK3CD (0.61) | PIK3CDPIK3C2BPIK3CGPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472160-B1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-19 | — | — | US | disclosed |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| WO-2017216292-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3C2B 7/4885PIK3CG 5/4885 |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3C2B 7/4885PIK3CG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.